Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER 6 monthly PF-08653944 in adults with overweight or obesity
2026-525318-75-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in Overweight and obesity comparing PF-08653944 once-monthly with Placebo to match PF-08653944 (2 arms). Primary endpoint: Body weight percent change from baseline at Week 72. Planned start Oct 2026; status: authorised.
02
Drugs
PF-08653944
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on 2026-525318-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525318-75-00.